On Thursday, Amgen, Inc. (NASDAQ:AMGN) have opened up about the new plans about how the company will actually handle the request for the new information asked by the Food and Drug Administration panel. Many analysts and the CEO of Amgen believe that there is nothing much to worry about like many investors did believe that FDA’s delay over Amgen’s denosumab will lead to the fall of Amgen’s shares in the market.http://www.favstocks.com/amgen-plan-for-...
The company’s CEO stated that there they will be able to provide FDA with the demands they have and hence this delay will not affect or damage its near-term revenue prospects.